TEVA-RISEDRONATE TABLET

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

RISEDRONATE SODIUM (RISEDRONATE SODIUM MONOHYDRATE)

থেকে পাওয়া:

TEVA CANADA LIMITED

এটিসি কোড:

M05BA07

INN (আন্তর্জাতিক নাম):

RISEDRONIC ACID

ডোজ:

35MG

ফার্মাসিউটিকাল ফর্ম:

TABLET

রচনা:

RISEDRONATE SODIUM (RISEDRONATE SODIUM MONOHYDRATE) 35MG

প্রশাসন রুট:

ORAL

প্যাকেজ ইউনিট:

4/30

প্রেসক্রিপশন টাইপ:

Prescription

থেরাপিউটিক এলাকা:

BONE RESORPTION INHIBITORS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0135301003; AHFS:

অনুমোদন অবস্থা:

APPROVED

অনুমোদন তারিখ:

2011-06-02

পণ্য বৈশিষ্ট্য

_ _
TEVA-RISEDRONATE
_ _
Page 1 of 54
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
TEVA-RISEDRONATE
Risedronate sodium tablets
Tablets, 5 mg, 30 mg, 35 mg and 150 mg (as the monohydrate), Oral
Teva Standard
Bisphosphonates (ATC Code: M05BA07)
Teva Canada Limited
30 Novopharm Court
Toronto, ON
M1B 2K9
Canada
www.tevacanada.com
Date of Initial Authorization:
October 10, 2013
Date of Revision:
April 18, 2023
Submission Control Number: 269246
_ _
TEVA-RISEDRONATE
_ _
Page 2 of 54
RECENT MAJOR LABEL CHANGES
1 INDICATIONS
04/2023
4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and Dosage
Adjustment
04/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
RECENT MAJOR LABEL CHANGES
.............................................................................................
2
TABLE OF CONTENTS
................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
4
1
INDICATIONS
.......................................................................................................................
4
1.1
Pediatrics
....................................................................................................................
5
1.2
Geriatrics
.....................................................................................................................
5
2
CONTRAINDICATIONS
..........................................................................................................
5
4
DOSAGE AND ADMINISTRATION
.........................................................................................
5
4.1
Dosing Considerations
.................................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
.............................................................. 5
4.4
Administration...................................